Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Regenxbio Inc’s stock clocked out at $6.55, down -1.80% from its previous closing price of $6.67. In other words, the price has decreased by -$1.80 from its previous closing price. On the day, 0.74 million shares were traded. RGNX stock price reached its highest trading level at $6.88 during the session, while it also had its lowest trading level at $6.41.
Ratios:
To gain a deeper understanding of RGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 3.05. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 30 ’24 when VITTAL VASISTA bought 20,041 shares for $7.41 per share.
KARABELAS ARGERIS N sold 10,000 shares of RGNX for $101,052 on Oct 01 ’24. The Director now owns 11,286 shares after completing the transaction at $10.11 per share. On Sep 03 ’24, another insider, KARABELAS ARGERIS N, who serves as the Director of the company, sold 10,000 shares for $11.56 each. As a result, the insider received 115,588 and left with 11,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 324520416 and an Enterprise Value of 214871216. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.85 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 2.548 whereas that against EBITDA is -0.961.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.30, which has changed by -0.704822 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $23.14, while it has fallen to a 52-week low of $5.62. The 50-Day Moving Average of the stock is -10.68%, while the 200-Day Moving Average is calculated to be -36.11%.
Shares Statistics:
It appears that RGNX traded 1.18M shares on average per day over the past three months and 922300 shares per day over the past ten days. A total of 49.53M shares are outstanding, with a floating share count of 44.72M. Insiders hold about 9.75% of the company’s shares, while institutions hold 87.22% stake in the company. Shares short for RGNX as of 1740700800 were 6280862 with a Short Ratio of 5.34, compared to 1738281600 on 6408552. Therefore, it implies a Short% of Shares Outstanding of 6280862 and a Short% of Float of 16.580000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Regenxbio Inc (RGNX) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $2.01, with high estimates of $2.65 and low estimates of $0.85.
Analysts are recommending an EPS of between $2.63 and -$2.91 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$3.56, with 3.0 analysts recommending between -$1.31 and -$5.17.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $20.51M. It ranges from a high estimate of $25.72M to a low estimate of $15M. As of the current estimate, Regenxbio Inc’s year-ago sales were $15.62MFor the next quarter, 5 analysts are estimating revenue of $171.39M. There is a high estimate of $231.73M for the next quarter, whereas the lowest estimate is $25.72M.
A total of 11 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $495.52M, while the lowest revenue estimate was $203M, resulting in an average revenue estimate of $314.86M. In the same quarter a year ago, actual revenue was $83.33MBased on 7 analysts’ estimates, the company’s revenue will be $196.27M in the next fiscal year. The high estimate is $350.2M and the low estimate is $110M.
